These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 23078653)

  • 1. Relapsed acute promyelocytic leukemia in a hemodialysis-dependent patient treated with arsenic trioxide: a case report.
    Emmons GS; Steingart RH; Stewart JA; Mertens WC
    J Med Case Rep; 2012 Oct; 6():355. PubMed ID: 23078653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of arsenic trioxide in a hemodialysis-dependent patient with relapsed acute promyelocytic leukemia.
    Perreault S; Moeller J; Patel K; Eyler R; Pham T; Russell K; Podoltsev N
    J Oncol Pharm Pract; 2016 Aug; 22(4):646-51. PubMed ID: 25972392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment of relapsed acute promyelocytic leukemia with arsenic trioxide in a hemodialysis-dependent patient: A case report.
    Lee HJ; Park SG
    World J Clin Cases; 2020 Nov; 8(21):5347-5352. PubMed ID: 33269269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia.
    Ohnishi K; Yoshida H; Shigeno K; Nakamura S; Fujisawa S; Naito K; Shinjo K; Fujita Y; Matsui H; Takeshita A; Sugiyama S; Satoh H; Terada H; Ohno R
    Ann Intern Med; 2000 Dec; 133(11):881-5. PubMed ID: 11103058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of a case of relapsed acute promyelocytic leukemia with arsenic trioxide.
    Hirayama Y; Koyama R; Nagai T; Ohta H; Kondo A; Ishikawa K; Ishitani K; Matsunaga T; Sakamaki S; Niitsu Y
    Intern Med; 2001 Nov; 40(11):1136-9. PubMed ID: 11757771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [All-trans retinoic acid/arsenic trioxide combination therapy for a patient with acute promyelocytic leukemia on dialysis].
    Nagao R; Hosoba R; Yahagi Y; Gunji T; Uryu H; Hattori D; Momoki M; Yamazaki H
    Rinsho Ketsueki; 2019; 60(10):1431-1435. PubMed ID: 31695003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy.
    Ghavamzadeh A; Alimoghaddam K; Ghaffari SH; Rostami S; Jahani M; Hosseini R; Mossavi A; Baybordi E; Khodabadeh A; Iravani M; Bahar B; Mortazavi Y; Totonchi M; Aghdami N
    Ann Oncol; 2006 Jan; 17(1):131-4. PubMed ID: 16227315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients.
    Niu C; Yan H; Yu T; Sun HP; Liu JX; Li XS; Wu W; Zhang FQ; Chen Y; Zhou L; Li JM; Zeng XY; Yang RR; Yuan MM; Ren MY; Gu FY; Cao Q; Gu BW; Su XY; Chen GQ; Xiong SM; Zhang TD; Waxman S; Wang ZY; Chen Z; Hu J; Shen ZX; Chen SJ
    Blood; 1999 Nov; 94(10):3315-24. PubMed ID: 10552940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of acute promyelocytic leukemia in a patient undergoing hemodialysis with arsenic trioxide.
    Hashimoto A; Tanaka Y; Shinzato I
    Clin Case Rep; 2021 Jul; 9(7):e04300. PubMed ID: 34322239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of relapsed acute promyelocytic leukemia by arsenic trioxide in Iran.
    Alimoghaddam K; Ghavamzadeh A; Jahani M; Mousavi A; Iravani M; Rostami S; Ghaffari H; Hosseini R; Jalili M
    Arch Iran Med; 2011 May; 14(3):167-9. PubMed ID: 21529103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two successful deliveries of healthy children by a young woman diagnosed and treated during induction and relapsed therapy for acute promyelocytic leukemia.
    Dang CC; Guan YK; Lau NS; Chan SY
    J Oncol Pharm Pract; 2020 Dec; 26(8):2034-2037. PubMed ID: 32279594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
    Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
    Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-adjusted arsenic trioxide for acute promyelocytic leukaemia in chronic renal failure.
    Firkin F; Roncolato F; Ho WK
    Eur J Haematol; 2015 Oct; 95(4):331-5. PubMed ID: 25600167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute renal failure, gastrointestinal bleeding, and cardiac arrhythmia after administration of arsenic trioxide for acute promyelocytic leukemia.
    Cashin R; Burry L; Peckham K; Reynolds S; Seki JT
    Am J Health Syst Pharm; 2008 May; 65(10):941-6. PubMed ID: 18463343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of Chromosomal Karyotype on the Prognosis of Patients with Acute Promyelocytic Leukemia in Condition of the Maintenance Treatment Based on Arsenic Trioxide].
    Lai BB; Mu QT; Zhang YL; Chen Y; Ouyang GF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Oct; 27(5):1380-1386. PubMed ID: 31607287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of acute promyelocytic leukemia in a patient under hemodialysis with arsenic trioxide.
    Hashimoto A; Tanaka Y; Ishikawa T; Shinzato I
    Clin Case Rep; 2021 Jul; 9(7):e04417. PubMed ID: 34322242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
    Leu L; Mohassel L
    Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia.
    Zhang Y; Wu S; Luo D; Zhou J; Li D
    PLoS One; 2016; 11(1):e0147545. PubMed ID: 26812490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and the Adverse Effects of Oral Versus Intravenous Arsenic for Acute Promyelocytic Leukemia: A Meta-Analysis of Randomized-Controlled Studies.
    Sasijareonrat N; Jahn N; Ungprasert P; Owattanapanich W
    Technol Cancer Res Treat; 2020; 19():1533033820937008. PubMed ID: 32583728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term remission after first-line single-agent treatment with arsenic trioxide of relapsed acute promyelocytic leukemia in an 8-year-old boy.
    Ebinger M; Schwarze CP; Feuchtinger T; Scheel-Walter HG; Lang P; Hildenbrand S; Gessler P; Handgretinger R
    Pediatr Hematol Oncol; 2011 May; 28(4):334-7. PubMed ID: 21345080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.